PPAR Research

Pharmacological and Toxicological Advances in PPAR-Related Medicines


Publishing date
06 Jul 2012
Status
Published
Submission deadline
06 Jan 2012

Lead Editor

1Department of Nephrology Internal Medicine, Shinshu University School of Medicine, Matsumoto 390-8621, Japan

2Department of Pathology and Molecular Medicine, Department of Pharmacology, and Toxicology Cancer Research Institute, Queen's University, Kingston, ON, Canada K7L 3N6

3Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden


Pharmacological and Toxicological Advances in PPAR-Related Medicines

Description

Peroxisome proliferator-activated receptors (PPARs), members of the nuclear receptor superfamily of ligand-binding transcription factors, are involved in the pathophysiology of the various types of diseases, especially in dyslipidemia, diabetes mellitus, metabolic syndrome, and major organ dysfunction such as liver, heart, and kidney. Many types of PPAR-related medicines have been developed and utilized clinically all over the world. Since PPARs are known to exert multieffects including regulation of hypolipidemic, antidiabetic, anti-inflammatory, antifibrotic, and antiproliferative pathways, the potential benefits and indications of these medicines are expected to extend further. On the other hand, these medicines may also exert various toxicities. In fact, some PPAR drugs are no longer in use clinically because of serious complications arising in some patients. Thus, we feel it necessary to understand the Yin and Yang effects of these medicines, and to definitively clarify their therapeutic usefulness for appropriate clinical utilization. We invite authors to submit original research and/or review articles that seek to define the novel beneficial or toxic effects of these medicines in human disease and also in animal models. Potential topics include, but are not limited to:

  • Novel beneficial effects or toxicities of PPAR-related medicines
  • Novel mechanism underlying beneficial effects or toxicities of PPAR-related medicines
  • Characterization of beneficial or adverse effects of recently developed PPAR-related medicines
  • Identification of new targets of the PPAR-related medicines
  • Identification of novel valuable biomarkers/clinical indicators that would improve clinical-utilization of PPARs-related medicines
  • Clinical studies investigating novel therapeutic or unexpected adverse effects of PPAR-related medicines
  • Confounding factors in humans or animals that influence the Yin and Yang effects of PPAR-related medicines

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ppar/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 940964
  • - Editorial

Pharmacological and Toxicological Advances in PPAR-Related Medicines

Yuji Kamijo | Christopher J. Nicol | Stefan E. H. Alexson
  • Special Issue
  • - Volume 2012
  • - Article ID 504918
  • - Review Article

PPAR Medicines and Human Disease: The ABCs of It All

Anthony J. Apostoli | Christopher J. B. Nicol
  • Special Issue
  • - Volume 2012
  • - Article ID 946943
  • - Review Article

The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination

Graham Skelhorne-Gross | Christopher J. B. Nicol
  • Special Issue
  • - Volume 2012
  • - Article ID 858352
  • - Review Article

Nutraceuticals as Ligands of PPAR

Meera Penumetcha | Nalini Santanam
  • Special Issue
  • - Volume 2012
  • - Article ID 201284
  • - Research Article

Plasticizers May Activate Human Hepatic Peroxisome Proliferator-Activated Receptor α Less Than That of a Mouse but May Activate Constitutive Androstane Receptor in Liver

Yuki Ito | Toshiki Nakamura | ... | Tamie Nakajima
  • Special Issue
  • - Volume 2012
  • - Article ID 978687
  • - Review Article

Idealized PPAR 𝜸 -Based Therapies: Lessons from Bench and Bedside

Angélica Amorim Amato | Francisco de Assis Rocha Neves
  • Special Issue
  • - Volume 2012
  • - Article ID 483536
  • - Research Article

Peroxisome Proliferator-Activated Receptor Agonists Differentially Regulate Inhibitor of DNA Binding Expression in Rodents and Human Cells

María del Carmen González | J. Christopher Corton | ... | Carlos Bocos
  • Special Issue
  • - Volume 2012
  • - Article ID 483656
  • - Review Article

Effects of PPARγ Ligands on Leukemia

Yoko Tabe | Marina Konopleva | ... | Akimichi Ohsaka
  • Special Issue
  • - Volume 2012
  • - Article ID 802384
  • - Review Article

The Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury

M. Elias-Miró | M. B. Jiménez-Castro | ... | C. Peralta
  • Special Issue
  • - Volume 2012
  • - Article ID 976089
  • - Research Article

PPARα Activation Protects against Anti-Thy1 Nephritis by Suppressing Glomerular NF-κB Signaling

Koji Hashimoto | Yuji Kamijo | ... | Toshifumi Aoyama
PPAR Research
 Journal metrics
Acceptance rate44%
Submission to final decision48 days
Acceptance to publication38 days
CiteScore7.100
Impact Factor2.953
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.